RPRX vs GMAB
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
RPRX · Royalty Pharma$67.30 ▼ 0.40%
GMAB · Genmab$53.63 ▲ 1.69%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- RPRX +78.0%
- GMAB +84.5%
Head to head
| Metric | RPRX | GMAB |
|---|---|---|
| Price | $67.30 | $53.63 |
| Change today | ▼ 0.40% | ▲ 1.69% |
| Market cap | $29.97B | $33.47B |
| Return, 3 months | +16.6% | +73.7% |
| Return, year to date | +76.6% | +74.1% |
| Return, 1 year | +77.9% | +87.1% |
| P/E (TTM) | 44.0 | 45.8 |
| P/B | 4.4 | 5.3 |
| P/E percentile vs own 5y | 84th | 84th |
| Dividend yield | 1.37% | – |
| Revenue growth (YoY, latest qtr) | +16.5% | +16.1% |
| Net profit growth (YoY) | -12.0% | -14.7% |
| Gross margin | – | 92.7% |
| Operating margin | 62.3% | 30.6% |
| Net margin | 32.0% | 17.0% |
| Return on equity | 12.3% | 12.1% |
| Analyst target vs. price | +5.0% | +20.7% |
| Analyst buy share | 100% | 89% |
| RSI (14) | 72 | 71 |
| 30-day volatility | 23.1% | 86.7% |
| Max drawdown, 1 year | -12.1% | -32.5% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- GMAB is the largest of the group by market value.
- GMAB has returned the most over the past year.
- RPRX carries the lowest trailing P/E.
- RPRX is growing revenue fastest.
- RPRX keeps the most profit per dollar of sales.
- RPRX has been the calmest stock over the last 30 days.